Iovance Biotherapeutics (LTS:0JDK) ROCE % : -40.86% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Iovance Biotherapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Iovance Biotherapeutics's annualized ROCE % for the quarter that ended in Sep. 2024 was -40.86%.

Iovance Biotherapeutics ROCE % Historical Data

The historical data trend for Iovance Biotherapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics ROCE % Chart

Iovance Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-53.59

-51.40

-48.90

-63.28

-74.13

Iovance Biotherapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-66.22	-67.77	-64.65	-49.20	-40.86

Iovance Biotherapeutics ROCE % Calculation

Iovance Biotherapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-460.559	/	( ( (663.982 - 91.485)	+	(780.351 - 110.306) )	/ 2 )
	=	-460.559	/	( (572.497	+	670.045)	/ 2 )
	=	-460.559	/	621.271
	=	-74.13 %

Iovance Biotherapeutics's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-356.268	/	( ( (964.322 - 93.639)	+	(991.115 - 118.056) )	/ 2 )
	=	-356.268	/	( ( 870.683	+	873.059 )	/ 2 )
	=	-356.268	/	871.871
	=	-40.86 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Iovance Biotherapeutics (LTS:0JDK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Iovance Biotherapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Iovance Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (LTS:0JDK) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

IOVA:USA 2LB:Germany

Address

825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.iovance.com

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Iovance Biotherapeutics Headlines

No Headlines